Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Deferred Revenue / Contract Liabilities by Year
Deferred Revenue / Contract Liabilities — Government COVID-19 supply agreements ($M) ($M)
Pfizer Deferred Revenue / Contract Liabilities: $1,500M in FY2025, down 31.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Advance customer/government payments and contracted multi-year delivery obligations under ASC 606.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred Revenue / Contract Liabilities — Government COVID-19 supply agreements ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,500 | -31.8% | Form 10-Q (filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 2,200 | -56.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 5,100 | – | Form 10-K (filed 2025-02-27) ↗ |
Breakdown
What makes up deferred Revenue / Contract Liabilities
- Government COVID-19 contract liabilities — Current ($M)689 · FY2025
- Government COVID-19 contract liabilities — Noncurrent ($M)826 · FY2025
- Remaining Performance Obligations (RPO) — Comirnaty multi-year contracts ($M)2,100 · FY2025
- Remaining Performance Obligations (RPO) — Paxlovid multi-year contracts ($M)1,000 · FY2025
- Remaining Performance Obligations (RPO) — Total [legacy through Q3 2023] ($M)15,000 · FY2022
- Unconditional Long-Term Purchase Obligations — Manufacturing, API & R&D ($M)5,000 · FY2025
Cite this data
StockData. (2026). Pfizer Deferred Revenue / Contract Liabilities ($M), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/def-rev-gov-covid-tot
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.